Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$6.32 USD
+0.33 (5.51%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $6.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Amicus Therapeutics, Inc. has a PEG ratio of 0.76 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.28.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
FOLD 6.32 +0.33(5.51%)
Will FOLD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FOLD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FOLD
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates
FOLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Moderna (MRNA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for
New Strong Sell Stocks for June 3rd
Other News for FOLD
Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200
Amicus Therapeutics Inc (FOLD) Q2 2025 Earnings: EPS of -$0. ...
Amicus Therapeutics (FOLD) Projects Positive Financial Outlook for FY25
Amicus (FOLD) Reports Strong Q2 Revenue and Projects Future Growth
Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates | ...